Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and PD of Single Dose Teverelix TFA in Healthy Men
NCT03781947Phase 1Completed
- Sponsor
- Antev
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of teverelix in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) (4 arms), sponsored by Antev. Primary endpoints: Area Under the Curve from time 0 to time t at 12 weeks, Maximum Plasma Concentration at 12 weeks and 2 more. Started Nov 2018; status: completed.
02
Drugs
teverelix
03
Conditions
prostate cancer (PCa)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT03781947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781947.